Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021

Faculty Medicine Year: 2025
Type of Publication: ZU Hosted Pages:
Authors:
Journal: The Lancet Public Health Elsevier Volume: 3
Keywords : Changing life expectancy , European countries 1990–2021:    
Abstract:
Background Decades of steady improvements in life expectancy in Europe slowed down from around 2011, well before the COVID-19 pandemic, for reasons which remain disputed. We aimed to assess how changes in risk factors and cause-specific death rates in different European countries related to changes in life expectancy in those countries before and during the COVID-19 pandemic. Methods We used data and methods from the Global Burden of Diseases, Injuries, and Risk Factors Study 2021 to compare changes in life expectancy at birth, causes of death, and population exposure to risk factors in 16 European Economic Area countries (Austria, Belgium, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Luxembourg, the Netherlands, Norway, Portugal, Spain, and Sweden) and the four UK nations (England, Northern Ireland, Scotland, and Wales) for three time periods: 1990–2011, 2011–19, and 2019–21. Changes in life expectancy and causes of death were estimated with an established life expectancy cause-specific decomposition method, and compared with summary exposure values of risk factors for the major causes of death influencing life expectancy. Findings All countries showed mean annual improvements in life expectancy in both 1990–2011 (overall mean 0·23 years [95% uncertainty interval [UI] 0·23 to 0·24]) and 2011–19 (overall mean 0·15 years [0·13 to 0·16]). The rate of improvement was lower in 2011–19 than in 1990–2011 in all countries except for Norway, where the mean annual increase in life expectancy rose from 0·21 years (95% UI 0·20 to 0·22) in 1990–2011 to 0·23 years (0·21 to 0·26) in 2011–19 (difference of 0·03 years). In other countries, the difference in mean annual improvement between these periods ranged from –0·01 years in Iceland (0·19 years [95% UI 0·16 to 0·21] vs 0·18 years [0·09 to 0·26]), to –0·18 years in England (0·25 years [0·24 to 0·25] vs 0·07 years [0·06 to 0·08]). In 2019–21, there was an overall decrease in mean annual life expectancy across all countries (overall mean –0·18 years [95% UI –0·22 to –0·13]), with all countries having an absolute fall in life expectancy except for Ireland, Iceland, Sweden, Norway, and Denmark, which showed marginal improvement in life expectancy, and Belgium, which showed no change in life expectancy. Across countries, the causes of death responsible for the largest improvements in life expectancy from 1990 to 2011 were cardiovascular diseases and neoplasms. Deaths from cardiovascular diseases were the primary driver of reductions in life expectancy improvements during 2011–19, and deaths from respiratory infections and other COVID-19 pandemic-related outcomes were responsible for the decreases in life expectancy during 2019–21. Deaths from cardiovascular diseases and neoplasms in 2019 were attributable to high systolic blood pressure, dietary risks, tobacco smoke, high LDL cholesterol, high BMI, occupational risks, high alcohol use, and other risks including low physical activity. Exposure to these major risk factors differed by country, with trends of increasing exposure to high BMI and decreasing exposure to tobacco smoke observed in all countries during 1990–2021. Interpretation The countries that best maintained improvements in life expectancy after 2011 (Norway, Iceland, Belgium, Denmark, and Sweden) did so through better maintenance of reductions in mortality from cardiovascular diseases and neoplasms, underpinned by decreased exposures to major risks, possibly mitigated by government policies. The continued improvements in life expectancy in five countries during 2019–21 indicate that these countries were better prepared to withstand the COVID-19 pandemic. By contrast, countries with the greatest slowdown in life expectancy improvements after 2011 went on to have some of the largest decreases in life expectancy in 2019–21. These findings suggest that government policies that improve population health also build resilience to future shocks. Such policies include reducing population exposure to major upstream risks for cardiovascular diseases and neoplasms, such as harmful diets and low physical activity, tackling the commercial determinants of poor health, and ensuring access to affordable health services
   
     
 
       

Author Related Publications

  • Aly Mohamed Abdelrahman Saad, "The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe The Euro Heart Survey on diabetes and the heart", Elsevier, 2004 More
  • Aly Mohamed Abdelrahman Saad, "Treatment and Health Status in Patients with Proven Coronary Artery Disease, but Ineligible for Revascularization. A Report from the Euro Heart Survey on Revascularization", Sage, 2006 More
  • Aly Mohamed Abdelrahman Saad, "Pharmacological treatment and perceived health status during 1-year follow up in patients diagnosed with coronary artery disease, but ineligible for revascularization: Results from the Euro Heart Survey on coronary revascularization", Sage, 2006 More
  • Aly Mohamed Abdelrahman Saad, "A 1-year follow up in patients diagnosed with coronary artery disease, but ineligible for revascularization. Results from The Euro Heart Survey on Coronary Revascularization", Oxford University Press, 2006 More
  • Aly Mohamed Abdelrahman Saad, "Atrial fibrillation management: a prospective survey in ESC Member Countries", Oxford University Press, 2005 More

Department Related Publications

  • Mohammed Ibrahim Amin Ibrahim Musa, "HbA1c And Insulin Resistance As Predictors For The Severity Of Coronary Artery Disease And Systolic Heart Failure In Non Diabetic Patients.", مجله كليه الطب البشري - جامغه الزقازيق, 2014 More
  • Muntasir Mustafa Ahmad, "قيمة الاجابة مضيق الشرايين التاجيين كمؤشر لضيق الشريان الكلوي", لايوجد, 1900 More
  • Muntasir Mustafa Ahmad, "قيمة سملة البطتنة والقيمة الوسطي للشرايين كعامل غير نافذ للتنبؤ بمرض الشريان التاجي", لايوجد, 1900 More
  • Muntasir Mustafa Ahmad, "المسافة بين نقطة التقاء وريقات الصمام الميترالي ومستواة الحلقي كمؤشر ", لايوجد, 1900 More
  • Muntasir Mustafa Ahmad, "قياس حركة ومسدحة الحلقة الشرفية الثلاثية كوسيلة لتنظيم وظيفة القلب ", لايوجد, 1900 More
Tweet